The government’s investigation into Valeant isn’t a reason to sell the stock, but there are plenty of other reasons not to own it, according to TheStreet’s Jim Cramer. He says you shouldn’t like Valeant for the balance sheet and for the fact that they company has overpromised and may see drug prices roll back. As far as the investigation goes, Cramer says the government is simply playing catch-up. He points out that an investigation into Bristol-Myers
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
